Medtronic, Bos Sci ordered to pay J&J about $1.2B for stent patents

The U.S. District Court in Delaware has awarded Johnson & Johnson (J&J) damages totaling $406.7 million and pre-judgment interest totaling $296 million from Boston Scientific and $521 million from Medtronic, in a case involving a stent patent owned by J&J.

Boston Scientific said it will appeal the judgment.

On Sept. 15, the U.S. Delaware District Court Judge Sue Robinson Monday granted J&J’s subsidiary, Cordis, a motion for final judgment against Boston Scientific and Medtronic, in their cases involving Cordis’ Palmaz balloon expandable stent patent.

The case relates to GFX and Microstent II from the Minneapolis-based Medtronic and the NIR stent from the Natick, Mass.-based Boston Scientific.

The original suit was filed in 1997, and Boston Scientific said it has not sold the NIR stent since 2004.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.